In a Ponte di Legno cohort of patients treated prior to the incorporation of the tyrosine kinase inhibitor imatinib into the therapeutic regimen for children with Ph+ ALL, IKZF1 deletion conferred an inferior 4-year disease-free survival (DFS) of 30% versus 58% in those with wild-type IKZF1 [61]. This evidence concerns the gene IKZF1 and acute lymphoblastic leukemia.